20.500.12556/DiRROS-8145 Lynparza (olaparib) : novo tarčno zdravilo pri raku jajčnikov Lynparza (olaparib) : New Mmedicine for targeted therapy of ovarian cancer A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib). Olaparib was registered based on a subanalysis of a study in phase II (9), in which patients with BRCA1/2 gene mutation who received olaparib lived 7 months longer without the disease progressing than patients that were not administered this medicine (11 months vs. 4 months); the difference was statistically relevant (HR 0.18; p < 0.00001). There were no differences in total survival of patients. Olaparib is an oral medication in capsules, so patients can take it at home. The available data shows that the most frequent side effects were nausea and fatigue. 25% of patients took olaparib for two years or more and the therapy was rarely discontinued due to side effects (only 9% of patients), which shows that patients usually tolerate olaparib well, which is a great advantage compared to chemotherapy, which was so far the only available treatment for recurring ovarian cancer (9). rak jajčnikov tarčna zdravila kemoterapija dedni raki true false true Slovenski jezik Angleški jezik by Authors Neznano 2018-01-03 12:19:11 2018-01-03 12:20:28 2022-08-16 09:56:15 0000-00-00 00:00:00 2016 0 0 str. 12-14 št. 1 Letn. 20 jun. 2016 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 618.1 1408-1741 2416763 65324032 RAZ_Skof_Erik_i2016.pdf RAZ_Skof_Erik_i2016.pdf 1 37B328CD7E07A7A79800651CD6B55CD1 8320a75170e3936545d31dade0c0a2fb0287142e1390de36c58108b659a11e41 46f8f79c-17b5-11ed-b6b8-001a4af901a5 20.500.12556/dirros/0a8348db-a511-405e-9e78-3dea12aebdba https://dirros.openscience.si/Dokument.php?lang=slv&id=10091 Onkološki inštitut Ljubljana Onkologija : strokovni časopis za zdravnike 0 0 0